CN103520487A - Novel application of medicinal composition - Google Patents
Novel application of medicinal composition Download PDFInfo
- Publication number
- CN103520487A CN103520487A CN201310491415.9A CN201310491415A CN103520487A CN 103520487 A CN103520487 A CN 103520487A CN 201310491415 A CN201310491415 A CN 201310491415A CN 103520487 A CN103520487 A CN 103520487A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- weight portions
- fructus
- pharmaceutical composition
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses novel application of a medicinal composition adopting epimedium, glossy privet fruit, radix polygonati officinalis, black soybean, sophora flower, mulberry, raspberry, American ginseng, donkey-hide gelatin, paecilomyces hepialid filament powder as main raw materials in preparing medicaments for treating diminished ovarian reserve and/or promoting endometrial development. The medicinal composition can be used for improving the ovarian reserve function, and promoting endometrial development by improving gynecologic endocrine function and increasing endometrium thickness, and has a wide application prospect.
Description
Technical field
The present invention relates to medical technical field, relate in particular to the application of a kind of pharmaceutical composition in the medicine for the preparation for the treatment of diminished ovarian reserve function and/or promotion Endometrium development.
Background technology
Diminished ovarian reserve function is the transition stage of premature ovarian failure, refers to that the ability that ovary produces ovum weakens, and follicle Quality Down causes female fertility ability to decline and the disease of sex hormone deficiency, is also called " ovarian senescence ".Clinical manifestation is Hypomenorrhea, hypomenorrhea, and even amenorrhea, infertile, with climacteric symptom in various degree, as hectic fever, hyperhidrosis, flush, emotional instability, hyposexuality, vaginal dryness, osteoporosis etc.If can not correct in time, likely develop into premature ovarian failure, from diminished ovarian reserve function to premature ovarian failure, be the process of a gradual change, studies have reported that about needs 6 months～6 year.
Change along with social development, cultural concept, living environment, operating pressure etc., increases diminished ovarian reserve function sickness rate year by year.The healthy reproduction that fertility forfeiture and the own serious threat women of low estrogen level occur earlier, has also increased the danger that women suffers from osteoporosis and coronary heart disease simultaneously.Prisoner this, early treatment's outbalance of ovarian reserve hypofunction.
In prior art, for the treatment of diminished ovarian reserve function, the most frequently used, effective method is hormone Replacement Therapy.Clinical studies show, hormone Replacement Therapy can make patient occur periodically menstruation, improves patient's genital atrophy and climacteric symptom, reduces osteoporotic generation, and its short term effect is obvious, but late result is undesirable; And chronicity swashs the sickness rate that rope replacement therapy can obviously increase the diseases such as carcinoma of endometrium, breast carcinoma.Therefore, finding safer, effectively to improve ovarian reserve function method is just expected by clinician.
Chinese medicine is according to " kidney storing essence ", " kidney governing reproduction ", " the kidney being the origin of congenital constitution " scheduling theory, think that ovary stores up each function reduction pathogenesis and belongs to traditional Chinese medical science deficiency of kidney-essence, deficiency of kidney yin, give the Therapeutic Method of replenishing essence the kidney invigorating, nourishing YIN and benefiting blood, can improve significantly ovarian reserve function, promote the recovery of menstruation, then increase menstrual blood volume, the infertile person of part is become pregnant, improve the climacteric symptoms such as hectic fever, hyperhidrosis, its late result is reliable, and treatment by Chinese herbs is safe and effective, therefore adopt Chinese medicine ovarian reserve hypofunction to there is important clinical value.
Endometrium is thin is women's common disease, and women is having under certain estrogenic effect, and while doing ultrasonic examination, endometrium can not reach the thickness of 8 millimeters to be just judged as endometrium thin.Cause reason that endometrium is thin to have general, common reason has that estrogen level is low, progesterone level is not enough and has ovulation failure and lack growth hormone etc., also there is local reason, inner film injury for example, adhesion and lack as etc., some patient is after artificial abortion, and endometrium is not yet recovered, and also can cause endometrium thin.Endometrium is thin will affect germ cell implantation, thus cause infertile, therefore, if find the little treatment means of good effect side effect to bring glad tidings for a large amount of infertile patients.
At present for the thin therapeutic modality of endometrium, mainly contain following several:
(1) estrogen
The first-selected Therapeutic Method of doctor trained in Western medicine aspect is complementing estrogen.Have and studies show that overlength estrogen supplements the pregnancy rate that (extended estrogen supplementation) can improve the thin women of endometrium that many plantations of IVF-ET are failed; But another supplements the demonstration of effectiveness study result about the thin women's ICSI of endometrium estrogen, start estrogen hCG day and supplement Clinical Pregnancy Rate in, survival rate of embryonic, abortion ratio, endometrium thickness all less than improving.Estrogen needs further to be observed to some thin patient's of hypoergia endometrium curative effect as can be seen here.
(2) low-dosage aspirin
The impact of aspirin on uterine blood flow: low-dosage aspirin can impel inner membrance to grow by regulating TXA2/PGI2 balance to increase uterus blood supply, improves the Endometrium development that clomifene causes bad, improves the endometrial state of holding.Also experimental results show that, low-dosage aspirin is on not impact of endometrium thickness, just it increases endometrium integrin beta 3(integrin beta 3 and expresses that to decline be likely a reason that causes thin temper Endometrium angiogenesis obstacle) expression intensity and MVD(microvessel density value, microvascular density) level, then increase endometrial endometrial receptivity, improve Embryo Implantation Rate in, not increase endometrium thickness.
(3) viagra
'Xiduofeng ' (sildenam), trade name viagra (viagra), it is nitric oxide sample medicine, it improves the cyclic guanosine monophosphate in tissue by suppressing the activity of PDE, act on uterine smooth muscle and uterine artery smooth muscle, improve endometrial blood supply, promote endometrium growth, improve endometrium receptivity.Studies show that, by oral or vaginal application viagra, can reach the effect of improving endometrium thickness and increasing Clinical Pregnancy Rate in; But the clinical effectiveness of had investigation and comparison viagra oral medication and these two kinds of occupation modes of vagina medicinal, result shows that vagina medicinal group (7/20) is higher than the cycle pregnancy rate of oral medication group (0/20), but the endometrium thickness zero difference of two groups of medications front and back.Therefore, the effect of viagra increase endometrium thickness still needs further research.
(4) pentoxifylline
Methylxanthine derivant pentoxifylline (PTX), is a kind of phosphodiesterase inhibitor, suppresses the decomposition of phosphodiesterase to cAMP, makes to keep in cell the cAMP of high concentration and to the generation of cytokine and effect landing regulating action.Studies show that, at IVF, be subject to the ovum cycle, use PTX and vitamin E therapeutic alliance, can increase endometrium thickness.Its mechanism is that PTX improves endometrium local T NF-α concentration, changes endometrial fibrosis state, for using high dose estrogen still can not reach to be satisfied with the patient of inner film thickness, is a kind of available therapeutic scheme.But due to the case number of this research less (only having 18 examples), and also less about the research of this respect, result also needs large-scale clinical trial to confirm.
(5) granulocyte colony-stimulating factor (G-CSF)
G-CSF successfully plays an important role to human reproduction.It can improve plantation embryo, affect Decidual Macrophage, affect ovulation, ovarian function, granulocyte function, inhibition autoimmune can, the habitual abortion rate of minimizing unknown cause.Studies show that, G-CSF promotes follicular development, increases the survival rate after embryo transfer, reduces abortion ratio.In uterine cavity, G-CSF perfusion is to treat at present the thin a kind of novel method of intractable endometrium.But in this Therapeutic Method raising auxiliary procreation technology, the curative effect of Embryo Implantation Rate in and pregnancy rate needs further to be observed.
Above Therapeutic Method improves the thin property of endometrium patient's pregnancy rate from improving endometrial blood flow or interior membrane-associated activity factor aspect, but very not clear and definite to the curative effect of increase endometrium thickness.
Theory of Chinese medical science thinks, the kidney being the origin of congenital constitution, main reproduction, and kidney is consistent with uterus, woman's reproductive process is centered by " kidney ".It is main treatment that the traditional Chinese medical science often adopts kidney tonifying, essence replenishing, benefiting QI and nourishing blood to invigorate blood circulation, and assistant, with the agent of the kidney warming, nourishing the liver, to reach increase endometrium thickness, increases uterine blood flow, promotes endometrium associated biomolecule active factors to express, thereby improves the object of inner membrance endometrial receptivity.And accumulating rich experience aspect treatment infertility.Therefore, adopt that Chinese medicine endometrium is thin has immeasurable bright prospects.
In prior art, take the pharmaceutical composition that Herba Epimedii, Fructus Ligustri Lucidi, Rhizoma Polygonati Odorati, Semen sojae atricolor, Flos Sophorae, Fructus Mori, Fructus Rubi, Radix Panacis Quinquefolii, Colla Corii Asini and Paecilomyces hepiali Chen et Dai Mycelia powder be primary raw material, through animal function test, prove to there is the health care of enhancing immunity and increase bone density; Yet there are no so far and use it for treatment diminished ovarian reserve function and the thin report of endometrium.
Summary of the invention
The pharmaceutical composition that to the object of the invention is to propose to take Herba Epimedii, Fructus Ligustri Lucidi, Rhizoma Polygonati Odorati, Semen sojae atricolor, Flos Sophorae, Fructus Mori, Fructus Rubi, Radix Panacis Quinquefolii, Colla Corii Asini and Paecilomyces hepiali Chen et Dai Mycelia powder be primary raw material is for the preparation for the treatment of diminished ovarian reserve function and/or promote the new purposes in the medicine of Endometrium development.
For reaching this object, the present invention by the following technical solutions:
In a purposes for the medicine for the preparation for the treatment of diminished ovarian reserve function and/or promotion Endometrium development, described pharmaceutical composition is comprised of Herba Epimedii, Fructus Ligustri Lucidi, Rhizoma Polygonati Odorati, Semen sojae atricolor, Flos Sophorae, Fructus Mori, Fructus Rubi, Radix Panacis Quinquefolii, Colla Corii Asini and Paecilomyces hepiali Chen et Dai Mycelia powder.
In above-mentioned application, as preferably, described pharmaceutical composition comprises: Herba Epimedii 15-35 weight portion, Fructus Ligustri Lucidi 10-20 weight portion, Rhizoma Polygonati Odorati 5-15 weight portion, Semen sojae atricolor 5-15 weight portion, Flos Sophorae 5-15 weight portion, Fructus Mori 5-15 weight portion, Fructus Rubi 5-15 weight portion, Radix Panacis Quinquefolii 1-5 weight portion, Colla Corii Asini 2-9 weight portion, Paecilomyces hepiali Chen et Dai Mycelia powder 1-5 weight portion.
More preferably, described pharmaceutical composition comprises: Herba Epimedii 16-32 weight portion, Fructus Ligustri Lucidi 12-18 weight portion, Rhizoma Polygonati Odorati 8-12 weight portion, Semen sojae atricolor 8-12 weight portion, Flos Sophorae 8-12 weight portion, Fructus Mori 8-12 weight portion, Fructus Rubi 8-12 weight portion, Radix Panacis Quinquefolii 2-4 weight portion, Colla Corii Asini 3-8 weight portion, Paecilomyces hepiali Chen et Dai Mycelia powder 2-4 weight portion.
Most preferably, described pharmaceutical composition comprises: Herba Epimedii 25 weight portions, Fructus Ligustri Lucidi 15 weight portions, Rhizoma Polygonati Odorati 10 weight portions, Semen sojae atricolor 10 weight portions, Flos Sophorae 10 weight portions, Fructus Mori 10 weight portions, Fructus Rubi 10 weight portions, Radix Panacis Quinquefolii 2.5 weight portions, Colla Corii Asini 5 weight portions, Paecilomyces hepiali Chen et Dai Mycelia powder 2.5 weight portions.
As preferably, described pharmaceutical composition also comprises that one or more are for improving or treat the medicine of accompanied symptoms; As in the situation that not affecting pharmaceutical composition effect, can add one or more for improving or treat the Chinese medicine of accompanied symptoms, such as: distention and pain of breast before menstruation can add Radix Bupleuri, Fructus Gardeniae, Radix Scutellariae etc.; Vexed insomnia can add Cortex Albiziae, Caulis Polygoni Multiflori, LONGMU etc.
As preferably, described pharmaceutical composition also comprises that the pharmaceutical carrier that pharmaceutically can accept is to make preparation; Such as by forms such as the agent of pharmaceutical carrier granulation, oral liquid, tablet, capsule, pills, adopt existing commercial process all can realize.
The invention also discloses described pharmaceutical composition and can take the method for any prior art, and add any other composition, for the preparation of the medicine of the decline for the treatment of ovarian function and/or promotion Endometrium development.
As preferably, described promotion Endometrium development is realized by improving gynecological's endocrine function and increasing endometrium thickness.
Beneficial effect of the present invention:
Take the pharmaceutical composition that Herba Epimedii, Fructus Ligustri Lucidi, Rhizoma Polygonati Odorati, Semen sojae atricolor, Flos Sophorae, Fructus Mori, Fructus Rubi, Radix Panacis Quinquefolii, Colla Corii Asini and Paecilomyces hepiali Chen et Dai Mycelia powder be primary raw material, while being applied to treat ovarian function decline, can improve ovarian reserve function, promote reproductive function, there is the effect of replenishing essence the kidney invigorating, nourishing blood for regulating menstruation, improve patient's genital atrophy and climacteric symptom; While being applied to promote Endometrium development, can improving gynecological's endocrine function and increase endometrium thickness; For Chinese medicine preparation safely and effectively.
The specific embodiment
Below by the specific embodiment, further illustrate technical scheme of the present invention.
Embodiment 1
The composition of pharmaceutical composition: Herba Epimedii 25 weight portions, Fructus Ligustri Lucidi 15 weight portions, Rhizoma Polygonati Odorati 10 weight portions, Semen sojae atricolor 10 weight portions, Flos Sophorae 10 weight portions, Fructus Mori 10 weight portions, Fructus Rubi 10 weight portions, Radix Panacis Quinquefolii 2.5 weight portions, Colla Corii Asini 5 weight portions, Paecilomyces hepiali Chen et Dai Mycelia powder 2.5 weight portions.
Embodiment 2
The composition of pharmaceutical composition: Herba Epimedii 16 weight portions, Fructus Ligustri Lucidi 12 weight portions, Rhizoma Polygonati Odorati 8 weight portions, Semen sojae atricolor 8 weight portions, Flos Sophorae 8 weight portions, Fructus Mori 8 weight portions, Fructus Rubi 8 weight portions, Radix Panacis Quinquefolii 2 weight portions, Colla Corii Asini 3 weight portions, Paecilomyces hepiali Chen et Dai Mycelia powder 2 weight portions.
Embodiment 3
The composition of pharmaceutical composition: Herba Epimedii 32 weight portions, Fructus Ligustri Lucidi 18 weight portions, Rhizoma Polygonati Odorati 12 weight portions, Semen sojae atricolor 12 weight portions, Flos Sophorae 12 weight portions, Fructus Mori 12 weight portions, Fructus Rubi 12 weight portions, Radix Panacis Quinquefolii 4 weight portions, Colla Corii Asini 8 weight portions, Paecilomyces hepiali Chen et Dai Mycelia powder 4 weight portions.
The pharmaceutical composition of above embodiment, while applying in following examples, uses the mode that be decocted in water for oral dose after mixing by Chinese medicine composition.
The therapeutical effect of embodiment 4 pharmaceutical compositions in diminished ovarian reserve function
Test method:
Ordinary circumstance:
Select clinically to meet patient's 50 examples of diminished ovarian reserve function, age 19-39 year, minimum 20 years old, maximum 39 years old, the shortest year in June of the course of disease, the longest 4.5 years.Be divided at random 2 groups, treatment group 25 examples, ages 34.47 scholar 5.72, the course of disease 3.02 scholars 0.42; Matched group 25 examples, ages 33.54 scholar 4.93, the course of disease 2.87 scholars 0.38; Two groups of age course of disease zero differences (p > 0.05), there is comparability.
Diagnostic criteria:
(1) symptom: delayed menstrual cycle, or very few through measuring, or amenorrhea, or infertile.
(2) biochemistry detection: the 3rd day extracting vein blood of menstrual cycle, measure serum hormone, 10mIU/ml<FSH (follicule-stimulating hormone (FSH))<40mIU/ml, FSH/LH (lutropin) ratio>3.6, estradiol (E2)>80pg/ml, three possesses one, can point out diminished ovarian reserve function.
Inclusive criteria:
(1) meet above-mentioned diagnostic criteria.
(2) treat the person that do not use medicine in first 1 month.
Exclusion standard:
(1) hypomenorrhea, or delayed menstrual cycle, or amenorrhea, or infertile be because congenital reproductive development is abnormal, or the day after tomorrow organic disease and damage and the person of causing.
(2) hyperprolactinemia, polycystic ovarian syndrome.
(3) oneself knows and maybe can be suspected to have breast carcinoma or have breast carcinoma medical history person, known tumor, thrombotic disease, liver function deviant and the psychotic that maybe can be suspected to have estrogen-dependent.
(4) nearly 3 months acceptance hormone medicine therapists.
Therapeutic scheme:
Treatment group adopts the formula in above-mentioned three kinds of embodiment, and wherein embodiment 1 is 9 examples, and embodiment 2,3 is 8 examples.Give Chinese medicine compound of the present invention with being decocted in water for oral dose.
Matched group adopts hormone therapy, and oral estradiol valerate 1mg qd serve on 21d, within latter 5 days, adds medroxyprogestetone acetate 10mg qd, drug withdrawal 3-7 days menstrual onset, more the same medication treatment, continuous 3 menstrual cycle.
Observation index:
(1) clinical observation on the therapeutic effect
Criterion of therapeutical effect: with reference to People's Republic of China's Chinese medicine industry standard---TCM Gynecology disease Standardization of diagnosis and curative effect.
1) drug withdrawal criterion of therapeutical effect in March:
Recovery from illness: recover normal through amount, menstrual period, cycle, can maintain 3 more than menstrual cycle;
Take a turn for the better: though recover normal through amount, menstrual period, cycle, can not maintain 3 more than menstrual cycle;
Invalid: symptom is without improvement.
2) drug withdrawal criterion of therapeutical effect in June:
Recovery from illness: recover normal through amount, menstrual period, cycle, can maintain 6 more than menstrual cycle;
Take a turn for the better: though recover normal through amount, menstrual period, cycle, can maintain 3-5 menstrual cycle;
Invalid: symptom is without improvement.
(2) gonadal hormone
The 3rd day extracting vein blood of menstrual cycle, measures serum and swashs rope, before observing treatment and treat latter 3 months, 6 months serum FSHs, the variation of FSH/LH ratio and E2.
(3) clinical symptoms
The improvement situation of the symptom such as hectic fever, hyperhidrosis, flush, emotional instability, insomnia, hyposexuality 6 months time before observing treatment and after drug withdrawal.
Result of study:
Drug withdrawal 3 months: matched group 20 examples of fully recovering, 3 examples that take a turn for the better, invalid 2 examples, total effective rate 92%; Treatment group 19 examples of fully recovering, 3 examples that take a turn for the better, invalid 3 examples, total effective rate 88%.Two groups of total effective rate there was no significant differences (P > 0.05).
Drug withdrawal 6 months: matched group 5 examples of fully recovering, 8 examples that take a turn for the better, invalid 12 examples, total effective rate 52%; Treatment group 8 examples of fully recovering, 12 examples that take a turn for the better, invalid 5 examples, total effective rate 80%, matched group and treatment group total effective rate have significant difference (P < 0.05); The average effectiveness level of three embodiment is 79.7%, 4 examples of wherein fully recovering in 1 group of 9 example of embodiment, 4 examples that take a turn for the better, invalid 1 example, effective percentage 89%; 3 examples of fully recovering in 2 group of 8 example of embodiment, 3 examples that take a turn for the better, invalid 2 examples, effective percentage 75%; 1 example of fully recovering in 3 group of 8 example of embodiment, 5 examples that take a turn for the better, invalid 2 examples, effective percentage 75%.Therefore,, in Chinese medicine composition of the present invention embodiment by weight ratio, the proportioning of embodiment 1 of take is best.
Between two groups of drug withdrawal 3 months: FSH, LH, E2 relatively, zero difference between group; With treatment before more all have statistical significance.Drug withdrawal 6 months: treatment group FSH is starkly lower than matched group (P < 0.0l), and E2 is apparently higher than matched group (P < 0.0l).Show that Chinese medicine compound short term effect and property swash rope and substitute therapeutic equivalence, late result is better than matched group, the results are shown in Table 1(treatment group and matched group and is mean scholar standard deviation).In addition in therapeutic process of the present invention, have no apparent side effect, follow up a case by regular visits to the sickness rate of diseases such as not increasing carcinoma of endometrium, breast carcinoma June.
Table 1, two groups of endocrine hormone comparisons
After two groups of climacteric sample symptom treatments, drug withdrawal no significant difference in March, after drug withdrawal June, the various symptom improvement for the treatment of group rate is obviously better than matched group, concrete outcome is in Table 2, improves before percentage rate=(before treatment-treatment after)/treatment.
Table 2, the comparison of two groups of symptom improvement rates
The therapeutical effect that embodiment 5 pharmaceutical compositions are thin to endometrium
Research is recruited:
Find the thin property of endometrium infertile patient (at least one menstrual cycle took that estradiol is more than or equal to 2mg/ days and around ovulation 1-2 days inner film thickness < 0.8cm in the past), 20 years old-45 years old age, person's 100 examples of signing Informed Consent Form voluntarily.
Excluded cases standard:
1) organic disease such as bilateral salpingemphraxis causes infertile person;
2) spouse is male infertility patient;
3) be associated with the serious primary disease such as cardiovascular and cerebrovascular vessel, liver, kidney and hemopoietic system;
4) do not meet inclusive criteria, not medication in accordance with regulations, cannot judge the not congruent judgement person of affecting the treatment of curative effect or data;
5) disturbance of intelligence, psychotic etc. mismatch therapist.
Grouping and administration:
The case of above-mentioned recruitment is divided into matched group and treatment group at random, every group of each 50 examples; Two groups of infertile time limits and infertile type there was no significant difference, two groups of data have harmony.Matched group: take estradiol 2mg/d; Treatment group: when 2mg/d takes estradiol, give in the usual way the pharmaceutical composition of embodiment 1.
Detect index:
(1) measure hormonal readiness, be included in ovulation day and measure LH, E2 and VEGF, measure E2, P and VEGF in midluteal phase.
(2) in ovulation day B ultrasonic, measure ovulation day endometrium thickness and Endometrial blood flow situation (RI, PI).Inner film thickness is got sagittal section and is measured the forward and backward flesh layer in uterus and inner membrance interface distance apart from 1.5cm-2cm place under palace.Ovulation day Endometrial blood flow detects: in uterus film is within the scope of 1-1.5cm at the bottom of palace, and colorful blood is the most obviously located, and with pulse Doppler, shows its frequency spectrum, obtains blood flow parameter: pulsatility index (PI), drag index (RI).
Result of study in Table 3, table 4 and table 5.
Table 3, two groups of ovulation day blood E2, LH, VEGF comparison
| Group | E2(pg/ml) | LH(mIU/ml) | VEGF(pg/ml) |
| Matched group | 225.36±113.24 | 17.32±6.23 | 101.63±46.81 |
| Treatment group | 360.82±86.31 | 26.32±5.26 | 212.00±92.63 |
Table 4, two groups of midluteal phase blood E2, P, VEGF comparison
| Group | E2(pg/ml) | P(ng/ml) | VEGF(pg/ml) |
| Matched group | 202.36±87.31 | 11.32±6.83 | 175.63±67.81 |
| Treatment group | 360.93±107.18 | 20.36±6.28 | 252.07±68.03 |
Table 5, two groups of ovulation day endometrium thickness, Uterine Artery Blood Flow comparison
| Group | Endometrium thickness (mm) | RI | PI |
| Matched group | 8.31±1.23 | 0.82±0.03 | 26.63±1.33 |
| Treatment group | 9.68±1.31 | 0.73±0.02 | 24.57±0.76 |
Table 3,4,5 demonstrations, treatment group raises compared with matched group in serum E2, LH, the VEGF level of ovulation day and midluteal phase; Treatment group obviously thickens compared with matched group in the endometrium thickness of ovulation day, and the RI of uterine artery and PI value obviously reduce compared with matched group.
Applicant statement, the present invention illustrates the present invention by above-described embodiment, but that the present invention is not limited to is above-mentioned, does not mean that the present invention must rely on above-mentioned could enforcement.Person of ordinary skill in the field should understand, any improvement in the present invention, to the selection of the interpolation of the equivalence replacement of the selected raw material of the present invention and auxiliary element, concrete mode etc., within all dropping on protection scope of the present invention and open scope.
Claims (7)
1. pharmaceutical composition is in a purposes for the medicine for the preparation for the treatment of diminished ovarian reserve function and/or promotion Endometrium development, and described pharmaceutical composition is comprised of Herba Epimedii, Fructus Ligustri Lucidi, Rhizoma Polygonati Odorati, Semen sojae atricolor, Flos Sophorae, Fructus Mori, Fructus Rubi, Radix Panacis Quinquefolii, Colla Corii Asini and Paecilomyces hepiali Chen et Dai Mycelia powder.
2. application according to claim 1, it is characterized in that, described pharmaceutical composition comprises: Herba Epimedii 15-35 weight portion, Fructus Ligustri Lucidi 10-20 weight portion, Rhizoma Polygonati Odorati 5-15 weight portion, Semen sojae atricolor 5-15 weight portion, Flos Sophorae 5-15 weight portion, Fructus Mori 5-15 weight portion, Fructus Rubi 5-15 weight portion, Radix Panacis Quinquefolii 1-5 weight portion, Colla Corii Asini 2-9 weight portion, Paecilomyces hepiali Chen et Dai Mycelia powder 1-5 weight portion.
3. application according to claim 2, it is characterized in that, described pharmaceutical composition comprises: Herba Epimedii 16-32 weight portion, Fructus Ligustri Lucidi 12-18 weight portion, Rhizoma Polygonati Odorati 8-12 weight portion, Semen sojae atricolor 8-12 weight portion, Flos Sophorae 8-12 weight portion, Fructus Mori 8-12 weight portion, Fructus Rubi 8-12 weight portion, Radix Panacis Quinquefolii 2-4 weight portion, Colla Corii Asini 3-8 weight portion, Paecilomyces hepiali Chen et Dai Mycelia powder 2-4 weight portion.
4. application according to claim 2, it is characterized in that, described pharmaceutical composition comprises: Herba Epimedii 25 weight portions, Fructus Ligustri Lucidi 15 weight portions, Rhizoma Polygonati Odorati 10 weight portions, Semen sojae atricolor 10 weight portions, Flos Sophorae 10 weight portions, Fructus Mori 10 weight portions, Fructus Rubi 10 weight portions, Radix Panacis Quinquefolii 2.5 weight portions, Colla Corii Asini 5 weight portions, Paecilomyces hepiali Chen et Dai Mycelia powder 2.5 weight portions.
5. according to the application described in claim 1-4 any one, it is characterized in that, described pharmaceutical composition also comprises that one or more are for improving or treat the medicine of accompanied symptoms.
6. according to the application described in claim 1-5 any one, it is characterized in that, described pharmaceutical composition also comprises the pharmaceutical carrier that pharmaceutically can accept.
7. according to the application described in claim 1-6 any one, it is characterized in that, described promotion Endometrium development is realized by improving gynecological's endocrine function and increasing endometrium thickness.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310491415.9A CN103520487B (en) | 2013-10-18 | 2013-10-18 | A kind of purposes of pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310491415.9A CN103520487B (en) | 2013-10-18 | 2013-10-18 | A kind of purposes of pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103520487A true CN103520487A (en) | 2014-01-22 |
| CN103520487B CN103520487B (en) | 2015-10-28 |
Family
ID=49923074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310491415.9A Active CN103520487B (en) | 2013-10-18 | 2013-10-18 | A kind of purposes of pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103520487B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105920087A (en) * | 2016-06-13 | 2016-09-07 | 河南百消丹药业集团有限公司 | Pill for regulating gynecological disease caused by female endocrine dyscrasia and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101461894A (en) * | 2007-12-20 | 2009-06-24 | 汉生堂药业有限公司 | Medicament composition for treating female climacteric syndrome and delaying age |
-
2013
- 2013-10-18 CN CN201310491415.9A patent/CN103520487B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101461894A (en) * | 2007-12-20 | 2009-06-24 | 汉生堂药业有限公司 | Medicament composition for treating female climacteric syndrome and delaying age |
Non-Patent Citations (1)
| Title |
|---|
| 吕雪良: "《求子》", 31 July 2009, article "子宫内膜薄", pages: 92 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105920087A (en) * | 2016-06-13 | 2016-09-07 | 河南百消丹药业集团有限公司 | Pill for regulating gynecological disease caused by female endocrine dyscrasia and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103520487B (en) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258685B (en) | Compound traditional Chinese medicine for treating diminished ovarian reserve and application | |
| CN105031559B (en) | It is a kind of to treat the Chinese medicine for causing infertility by Stein-Leventhal syndrome | |
| CN103638511A (en) | Postpartum stasis removing particles | |
| CN103349766A (en) | Pharmaceutical composition for endless postpartum lochia | |
| CN103520487B (en) | A kind of purposes of pharmaceutical composition | |
| CN104523889B (en) | A kind of Chinese medicine preparation for the treatment of habitual abortion and preparation method thereof | |
| CN101332282B (en) | Traditional Chinese medicine composition for treating gynecologic diseases from kidney deficiency and genitals coldness, and its preparation method | |
| CN108498705A (en) | Vagina doubts glue bolt and preparation method thereof | |
| CN103919911A (en) | New use of pharmaceutical composition | |
| CN102125671B (en) | Traditional Chinese medicinal composition for treating gynaecopathia caused by deficiency of the kidney and cold and preparation method thereof | |
| CN103071018A (en) | Traditional Chinese medicine preparation for treating early habitual abortion | |
| CN102755491B (en) | Chinese medicinal composition for treating threatened abortion | |
| CN105920166A (en) | Application of gynecological inflammation resistance preparation in preparation of medicine for preventing and treating chronic pelvic pain | |
| CN101152345B (en) | Traditional Chinese medicine preparation for treating female acyesis caused by ovulation obstacle | |
| CN104587408A (en) | New use of Qilin pills | |
| CN104042672B (en) | A kind of Chinese medicine compound prescription vaginal washing fluid and its preparation method and application | |
| CN103751747B (en) | A kind of Chinese medicine of medicine colporrhagia due to abortion disease | |
| CN107582948B (en) | Pharmaceutical composition for treating female irregular menstruation and preparation method and application thereof | |
| CN105560668A (en) | Pharmaceutical composition for curing immune infertility | |
| CN102114240B (en) | Application of medicament containing hirudin and cellosolve | |
| Wang et al. | Analysis of uterine artery and sex hormones in treating diminished ovarian reserve with tiaojing decoction | |
| CN101559147A (en) | Prescription of novel pure traditional Chinese medicine preparation for curing hysteromyoma | |
| CN105327067A (en) | Chinese herbal preparation for treating abortion postoperation internal secretion normal type hypomenorrhea | |
| CN105726868A (en) | Pharmaceutical preparation for treating first-trimester threatened abortion with anticardiolipin antibody positive | |
| CN104367593A (en) | New application of periplaneta americana |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160314 Address after: 100101 Beijing City, Chaoyang District Road No. 13 Building 1 small 9 room 9006 Patentee after: Beijing Prudential Investment Limited by Share Ltd Address before: 438300 Hubei City, Huanggang province Jinqiao City Jinqiao Development Zone Jinqiao Road, Hubei Fenghuang Baiyun Mountain Pharmaceutical Co., Ltd. Patentee before: Hubei Fenghuang Baiyunshan Pharmaceutical Co., Ltd. |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140122 Assignee: Beijing Acting Pharmaceutical Biotechnology Co., Ltd. Assignor: Beijing Prudential Investment Limited by Share Ltd Contract record no.: 2017990000177 Denomination of invention: Application of drug composition Granted publication date: 20151028 License type: Common License Record date: 20170511 |
|
| EE01 | Entry into force of recordation of patent licensing contract |